<DOC>
	<DOC>NCT02581644</DOC>
	<brief_summary>The purpose of the study is to determine a) if the implementation of belatacept patient alert card (PAC) resulted in effective understanding of key safety messages and b) if the degree of understanding of key safety messages is associated with improved clinical and safety outcomes.</brief_summary>
	<brief_title>Assessment of Effectiveness of Belatacept Patient Alert Card in Patients Following Renal Transplantation in a Sample of EU Countries</brief_title>
	<detailed_description>3 sub studies: 2 Cross-Sectional and 1 retrospective chart review</detailed_description>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Patient survey (cohort 1): Patients has taken belatacept within the previous 3 months for renal transplantation Patient is over 18 years of age HCP survey (cohort 2): Physician or nurses working in nephrology centers, with at least 1 patient taking belatacept in the previous 6 months for renal transplantation (by prescribing, administering or by follow up) Retrospective chart review study (cohort 3): Patient survey questionnaire received, Informed Consent Form (ICF) signed (if required) Patient survey: Patient has participated in a clinical trial for their renal condition in the previous 12 months Currently an employee of BMS HCP survey: Physicians or nurse who have recruited patients for the Patient survey Currently an employee of BMS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>